Using the Asthma Action Plan

The goal of therapy is control — an asthma action plan helps parents and caregivers help kids

In the treatment of pediatric asthma, an asthma action plan can help a child’s caregiver provide appropriate care. The National Asthma Education and Prevention Program (NAEPP)¹ recommends creating a written plan that includes instructions for the daily management of persistent asthma and actions to take if symptoms worsen. Talking parents or caregivers through the plan can help them understand the importance of daily therapy and when to seek help.¹

Download a sample asthma action plan (PDF - 576 KB)

Updated NHLBI/NAEPP guidelines stress control

In 2007, the NHLBI/NAEPP updated its clinical guidelines for managing asthma. The updated guidelines emphasize asthma control, avoiding overuse of rescue medications, ongoing monitoring, and the creation of a daily asthma action plan for parents to follow. These guidelines are aimed at achieving control.

Download the NHLBI/NAEPP guidelines (PDF - 214 KB)

Some files on this page require Adobe^® Reader^® to be installed. If you do not have Adobe Reader on your computer, you can download it here.

Enlarge Text:

Print:

PULMICORT RESPULES helps put control
within reach

For first-line treatment of persistent pediatric asthma across all severities.

Links to learn about other asthma treatment options for patients:

Indication

PULMICORT RESPULES is indicated for the maintenance treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.

PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of acute bronchospasm.

Important Safety Information

Inhaled corticosteroids may cause a reduction in growth velocity. The long-term effect on final adult height is unknown.

PULMICORT RESPULES, like other inhaled corticosteroids, may impact the hypothalamic-pituitary-adrenal axis, especially in susceptible individuals, in young children, and in patients given high doses for prolonged periods.

Particular care is needed for patients who are transferred from systemically active corticosteroids to less systemically available corticosteroids, because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids (see WARNINGS in full Prescribing Information).

Patients taking immunosuppressant doses of corticosteroids should avoid exposure to infections such as chicken pox and measles.

Common adverse events reported in clinical trials, regardless of relationship to treatment, included respiratory infection, rhinitis, coughing, otitis media, viral infection, gastroenteritis, ear infection, oral thrush/candidiasis, and epistaxis.

Please see accompanying full Prescribing Information (PDF).

Site Map | References | Contact Us